Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Tax Provisions: 2017-2024

Historic Tax Provisions for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $7.0 million.

  • Kiniksa Pharmaceuticals International's Tax Provisions rose 58.81% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 265.93%. This contributed to the annual value of $7.0 million for FY2024, which is 122.91% up from last year.
  • Kiniksa Pharmaceuticals International's Tax Provisions amounted to $7.0 million in FY2024, which was up 122.91% from -$30.7 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Tax Provisions registered a high of $7.0 million during FY2024, and its lowest value of -$172.3 million during FY2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Tax Provisions averaged around -$65.3 million, with its median value being -$30.7 million (2023).
  • Its Tax Provisions has fluctuated over the past 5 years, first soared by 351.69% in 2020, then slumped by 12,543.10% in 2022.
  • Kiniksa Pharmaceuticals International's Tax Provisions (Yearly) stood at $5.2 million in 2020, then plummeted by 73.12% to $1.4 million in 2021, then slumped by 12,543.10% to -$172.3 million in 2022, then spiked by 82.17% to -$30.7 million in 2023, then surged by 122.91% to $7.0 million in 2024.